Compare Gitlab Inc (GTLB) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Organon & Co. Common Stock — how do they compare? Gitlab Inc trades at $52.47 (market cap $8.86B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Gitlab Inc is far larger — about 2.5× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Organon & Co. Common Stock for 0 Days on average.
| GTLB | OGN | |
|---|---|---|
Market Cap | $8.86B | $3.61B |
Volume | 6,160,270 | 1,808,049 |
Sector | Technology | Health |
52-Week High | $56.01 | $13.81 |
52-Week Low | $19.42 | $5.70 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $7.60B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $51.95, down 7.25% today but maintains strong technical momentum with bullish moving averages. The company shows accelerating revenue growth, reaching $759M in 2025, with consistent earnings beats in recent quarters. Despite negative net margins, gross margins remain exceptional at 85.75%. Recent Q2 2026 results exceeded expectations, driving positive analyst sentiment and institutional interest.
Outlook remains positive with AI-driven demand and raised guidance, though high valuation multiples and persistent cash flow challenges present risks. Wall Street maintains a cautious 'Hold' consensus with $49.71 target, but recent earnings momentum suggests potential upside if execution continues.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
